VeriSIM Life

Global leader in AI based translational medicine

VeriSIM Life addresses the translational gap in drug development, de-risking R&D decisions through their computational BIOiSIMTM platform. Using AI and ML, BIOiSIMTM models the translation of compounds across seven species and reduces the failure rate in drug development.  The platform can be used before preclinical animal trial start, allowing earlier insights and savings in expensive outsourced experimentation.

The company is headquartered in San Francisco, California. 

View website

Why we invested in VeriSIM Life

Pharmaceutical companies need to become more efficient in the way they develop drugs. We are looking for digital disruption of the whole value chain of drug development and saw a clear gap in translational medicine.

VeriSIM Life helps pharma predict clinical outcomes in a pre-clinical stage and reduce the amount of preclinical experimentation needed – meaning also fewer animal trials – and ultimately bringing better treatments to patients. Debiopharm wants to build a sustainable future for drug development and in VeriSIM Life we saw a company that shares our values.

Are you also an entrepreneur seeking funding?

Discover how we can help you bring your ambition to life

Contact us

Meet Jo Varshney, CEO and Founder of VeriSIM Life


All News

Press Releases

All Press Releases